When Your Clinical Data Needs an Expert Panel: What Most Get Wrong

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

The requirement for expert panel consultations under MDR is not arbitrary. It exists because some devices operate in clinical contexts where the available evidence base is inherently limited, controversial, or rapidly evolving. In those situations, clinical judgment from independent experts becomes a regulatory necessity, not a formality.

Yet the way this requirement is applied in practice creates confusion. Manufacturers often wait too late to identify whether an expert panel is needed. When they do arrange one, the consultation is poorly scoped, the questions are too vague, and the documentation fails to meet the standard a Notified Body expects.

This post walks through when expert panels are required, how to structure the consultation properly, and what makes the difference between a deficiency and a complete submission.

What MDR Actually Says About Expert Panels

Annex XIV Part A of MDR outlines the content requirements for clinical evaluation. It states that where relevant scientific validity is not established through clinical evidence alone, manufacturers must consult an expert panel.

The regulation does not define “where relevant.” That ambiguity is intentional. It places the burden on manufacturers to justify whether their device, its intended use, and the available evidence require external clinical expertise.

MDCG 2020-6 provides additional guidance. It clarifies that expert panels are particularly relevant for implantable devices, devices with novel technologies, and devices where the clinical benefit-risk is difficult to assess from the literature or device data alone.

Still, the guidance does not give a checklist. You cannot automate the decision. You must assess the clinical context, the strength of your evidence, and the judgment capacity available within your organization.

The Triggers You Should Recognize Early

Most manufacturers wait until a Notified Body review to think about expert panels. By then, the clinical evaluation report is written, the technical file is assembled, and the timeline is locked. Adding an expert panel at that stage delays everything.

You should identify the need during clinical evaluation planning. Here are the situations where an expert panel becomes necessary:

First: Your device is the first in its category or uses a novel mechanism of action. There is no established clinical pathway, no consensus guidelines, and limited or no equivalent devices on the market. In this case, literature alone cannot validate your clinical claims. You need clinical experts who understand the disease, the treatment gap, and the risk profile to assess whether your approach is scientifically sound.

Second: The available clinical data shows conflicting results. Some studies report benefit, others do not. Risk profiles vary across populations. In this context, a manufacturer’s interpretation will not satisfy a reviewer. You need independent experts who can weigh the evidence, explain the discrepancies, and provide a clinical opinion on whether the device should be used despite the gaps.

Third: Your device is used in a vulnerable population or in an off-label context where standard evidence does not apply. Pediatrics, pregnancy, rare diseases, and palliative care all fall into this category. The literature is sparse. Clinical practice varies. Regulatory guidance is limited. Here, expert opinion becomes the backbone of your clinical evaluation.

Fourth: The benefit-risk assessment depends on subjective clinical judgment. For example, cosmetic devices with functional claims, diagnostic devices that change treatment decisions, or therapeutic devices where the endpoint is quality of life. These require clinicians who can interpret clinical relevance, not just statistical significance.

How to Structure the Consultation

An expert panel consultation is not a focus group. It is not a validation exercise where you present your claims and ask experts to agree. It is a structured process where you present clinical evidence, identify gaps, and ask experts to provide independent clinical reasoning.

The first step is selecting the experts. They must be independent. They cannot be involved in the design, development, or commercialization of the device. They must have relevant clinical experience in the disease area, patient population, or clinical setting where the device is used. Ideally, they should come from different institutions and different geographies to avoid bias.

MDCG 2020-6 recommends at least three experts. In practice, five is safer. If one expert has a conflict of interest or drops out, you still have a robust panel.

The second step is scoping the consultation. You must define exactly what you are asking the experts to assess. This requires clear, specific questions. Not “Is the device safe and effective?” but “Given the available clinical data and the absence of long-term implant studies, what is your clinical opinion on the benefit-risk for patients over 65 with comorbidities?”

Each question should map to a specific gap in your clinical evaluation. The expert panel should not be solving problems you should have solved with data. They should be providing clinical judgment where data cannot provide a definitive answer.

The third step is documentation. The consultation must be recorded in a structured report. Each expert’s qualifications, independence declaration, and responses must be documented separately. Majority and minority opinions must be presented. Any dissenting views must be acknowledged and addressed.

This report becomes part of your clinical evaluation report. It is not an attachment. It is integrated into the benefit-risk assessment and referenced throughout the clinical evaluation.

What Reviewers Actually Look For

When a Notified Body reviews an expert panel consultation, they do not just check that it happened. They assess whether it was meaningful.

First, they check independence. If one of your experts is a paid consultant, a key opinion leader you sponsor, or a co-author on your clinical studies, the consultation is compromised. Reviewers will question the objectivity of the opinions.

Second, they check relevance. Are the experts qualified to assess the clinical context? A cardiologist cannot credibly assess a neurosurgical device. A general practitioner cannot assess a highly specialized intervention. The expertise must match the clinical claim.

Third, they check the questions. Were they specific? Did they address real clinical gaps? Or were they vague and generic? A consultation that asks “Do you support the use of this device?” will fail. A consultation that asks “Given the absence of randomized data, what is your clinical opinion on the adequacy of the observational evidence for this population?” will pass.

Fourth, they check how you handled dissent. If one expert disagreed, did you ignore it? Did you dismiss it without justification? Or did you acknowledge it, explain the reasoning, and adjust your clinical evaluation accordingly? Reviewers expect transparency, not unanimity.

Fifth, they check integration. Does the expert panel report sit isolated in your technical file, or is it woven into your clinical evaluation? Are the expert opinions cited in your benefit-risk assessment? Are they referenced in your PMCF plan? If not, the consultation looks like a compliance exercise, not a clinical tool.

When You Do Not Need an Expert Panel

Not every device needs an expert panel. If your device has substantial equivalence to well-established devices, abundant clinical literature, and a clear benefit-risk supported by guidelines and consensus, an expert panel is not required.

If your clinical evaluation is based on strong clinical data from your own studies or from equivalent devices, and the benefit-risk is straightforward, you do not need external validation.

The decision not to consult an expert panel must still be justified. Your clinical evaluation report should include a section explaining why an expert panel was not necessary. This shows you considered the requirement and made a reasoned decision.

Notified Bodies respect this approach. What they do not respect is silence. If you never mention expert panels, reviewers will assume you overlooked the requirement.

Practical Implications for Your Clinical Evaluation Process

If you identify the need for an expert panel early, you can integrate it into your clinical evaluation timeline. The consultation happens before the report is finalized, and the expert opinions shape your benefit-risk conclusions.

If you wait until a Notified Body asks, you add months to your submission. You must recruit experts, brief them, conduct the consultation, document it, revise your clinical evaluation, and resubmit. All of this could have been avoided.

Expert panels are also valuable for PMCF planning. If experts identify clinical questions that cannot be answered with existing data, those questions become PMCF objectives. The consultation becomes a strategic input, not a regulatory burden.

Finally, expert panels strengthen your position in post-market surveillance. If an adverse event occurs, you already have documented clinical reasoning from independent experts. This protects your benefit-risk rationale and supports your vigilance decisions.

Final Observations

The requirement for expert panel consultations under MDR reflects a fundamental principle: clinical evidence is not always sufficient. In some contexts, clinical judgment is necessary to interpret that evidence and assess benefit-risk.

Manufacturers who recognize this early and structure their consultations properly gain a significant advantage. Their clinical evaluation reports are more robust, their submissions move faster, and their post-market surveillance is better informed.

Those who treat expert panels as a box to tick end up with deficiencies, delays, and rework.

The difference is not in the regulation. It is in how you apply it.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.